Miller‑Meeks pushes expanded non‑opioid access

Pain treatment is the domain here, but the real stakes are Medicare drug rules. A bipartisan group led by Rep. Mariannette Miller-Meeks asked CMS on May 4 to make it easier for seniors to get newer non-opioid pain medicines through Medicare Part D. The gap is pretty simple — Medicare covers lots of pain care in general, but newer prescription alternatives can still get stuck behind bad formulary placement, prior authorization, or higher out-of-pocket costs. That is what Miller-Meeks and 44 other lawmakers are trying to change. ### What happened? Miller-Meeks, an Iowa Republican and physician, said she led a bicameral group of 44 lawmakers in a letter to CMS Administrator Mehmet Oz urging the agency to use existing authority to expand access to non-opioid pain treatment options for Medicare beneficiaries. The letter focuses on Medicare Part D — the prescription-drug side of Medicare — not just general pain services. ### What are they asking CMS to do? Basically, three things. Put clinically appropriate non-opioid drugs in better formulary positions, cut back utilization-management rules that delay access, and align plan design with the idea that safer pain treatment can lower downstream harm. In plain English, the lawmakers want CMS to make plans stop treating newer non-opioid drugs like expensive exceptions while cheap generic opioids stay easy to reach. ### Why is Part D the pressure point? Because Medicare already covers a lot of pain management under Part B — physical therapy, acupuncture for chronic low back pain, behavioral health integration, and other services. But prescription drugs live under Part D or Medicare Advantage drug coverage, where each plan controls tiers, prior auth, and step therapy within CMS rules. So a senior can have “coverage” in theory and still hit a practical wall at the pharmacy counter. ### Isn’t Medicare already doing something on non-opioids? Yes — but mostly in outpatient surgery settings. CMS has a separate-payment framework for qualifying non-opioid pain drugs, biologics, and some devices under the NOPAIN Act from January 1, 2025 through December 31, 2027. That helps hospitals and ambulatory surgery centers use certain alternatives without absorbing the cost. The catch is that this facility-payment policy for filling a prescription after surgery or for acute pain. ### Why are lawmakers pushing now? Because the policy fight has moved from “should non-opioids exist” to “who can actually get them.” Miller-Meeks has also backed the Alternatives to PAIN Act, H.R. 1227, which would go further than this letter by requiring qualifying non-opioid pain drugs in Part D to sit on the lowest cost-sharing tier, skip the deductible, and avoid prior authorization and step therapy. The letter to CMS looks like the administrative version of that same push. ### What would this mean for seniors? If CMS acts, some Medicare beneficiaries could see faster access to newer pain drugs that do not act on opioid receptors, with fewer delays and potentially lower out-of-pocket costs. But nothing changes automatically yet — this is a request to the agency, not a final rule or enacted statute. Actual access would still depend on what CMS decides and how Medicare drug plans implement any new direction. ### What should community groups watch? Expect questions about eligibility, evidence, and cost. Seniors and caregivers will want to know which drugs qualify, whether a doctor has to try an opioid first, and whether a plan can still impose paperwork. Those are exactly the friction points this letter is trying to loosen, but they are also the details CMS would have to spell out. ### Bottom line? This is a Medicare benefit-design fight disguised as a pain-policy story. The big idea is not banning opioids — it is making sure non-opioid options are not harder to get than the drugs policymakers say they want to avoid.